Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.43 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.43 |
| ▸ | VIPR1 | P32241 | 3/20 | 0.42 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.40 |
| ▸ | TFPI | P10646 | 1/20 | 0.39 |
| ▸ | VIPR2 | P41587 | 3/20 | 0.39 |
| ▸ | NPY2R | P49146 | 4/20 | 0.39 |
| ▸ | NPY4R | P50391 | 4/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.39 |
| ▸ | NPY1R | P25929 | 3/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.39 |
| ▸ | BACE1 | P56817 | 2/20 | 0.38 |
| ▸ | GLP1R | P43220 | 1/20 | 0.38 |
| ▸ | GCGR | P47871 | 1/20 | 0.38 |
| ▸ | GIPR | P48546 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31013467 | 1.00 | SIRT2 (0.43) | SIRT2SIRT5VIPR1EPHA2TFPI | |
| SCHEMBL24451291 | 0.98 | SIRT2 (0.44) | SIRT2SIRT5VIPR1EPHA2VIPR2 | |
| SCHEMBL29658771 | 0.98 | SIRT2 (0.44) | SIRT2SIRT5VIPR1EPHA2VIPR2 | |
| SCHEMBL29648240 | 0.91 | EPHA2 (0.42) | SIRT2SIRT5VIPR1EPHA2TFPI | |
| SCHEMBL30543724 | 0.89 | SIRT2 (0.44) | SIRT2SIRT5VIPR1EPHA2VIPR2 | |
| SCHEMBL31031511 | 0.88 | SIRT2 (0.43) | SIRT2SIRT5VIPR1NPY4RNPY5R | |
| SCHEMBL30680476 | 0.88 | ENPEP (0.46) | VIPR1NPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL30123274 | 0.87 | GNPAT (0.43) | NPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL29604474 | 0.86 | ENPEP (0.44) | NPY4R | |
| SCHEMBL30988493 | 0.86 | NPY4R (0.43) | SIRT2SIRT5VIPR1NPY2RNPY4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240252662-A1 | PEPTIDE DRUG CONJUGATES SPECIFIC TO FIBRONECTIN ISOTYPES FOR CANCER THERAPY | CASE WESTERN RESERVE UNIVERSITY | 2024-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240252662-A1 | PEPTIDE DRUG CONJUGATES SPECIFIC TO FIBRONECTIN ISOTYPES FOR CANCER THERAPY | FN1, IDUA, INHA | SIRT2 4444/4885SIRT5 3529/4885VIPR1 1507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.